

Curriculum Vitae

Name: PAPANIMITRIU, Evangelia

Date of birth: August 20, 1967

Place of birth: Piraeus, Greece

Nationality: Greek

Address: Agias Kuriakis 30, GR26443 Patras, Greece

Tel/FAX: 0030 2610 962336

E-mail: epapad@upatras.gr

EDUCATION:

University: School of Pharmacy, University of Patras, Patras, Greece; 1985-1989. Degree: B. Pharm

Graduate: Department of Pharmacology, School of Medicine, University of Patras, Patras, Greece; 1990-1994; Degree: Ph.D. in Pharmacology

Postdoctoral: School of Medicine, University of Patras, Patras, Greece; 1994-1995
School of Natural Sciences, University of Patras, Patras, Greece; 1996
School of Medicine, University of Patras, Patras, Greece; 1997-1998

ACADEMIC APPOINTMENTS:

1991-1994: Research Assistant at the University of Wisconsin Medical School, Milwaukee Clinical Campus, Wisconsin, U.S.A.

1995-1997: Assistant Professor of Pharmacology at the Department of Nursing, Faculty of Professions of Health and Providence, Higher technological and Educational Institute of Patras, Greece.

1998-2003: Lecturer of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

2003-2009: Assistant Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

2009-2015: Associate Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

2015-present: Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

ACADEMIC ACTIVITIES:

1999-2000 Examiner of Pharmacology for candidate post-graduate fellows of the State Scholarships Foundation.

@2001-2004:

2000-present: Reviewer of research papers for Carcinogenesis, Journal of Vascular Research, Vascular Pharmacology, Evidence Based Complementary and Alternative Medicine, Recent Patents on Anti-Cancer Drug Discovery, Journal of Cancer Research and Clinical Oncology, BMC Cardiovascular Disorders, Arthritis and Rheumatism, Cancer Letters, Biochemical Pharmacology, Medicinal Research Reviews, Cell Biology International, Biopolymers, Archives of Biochemistry & Biophysics,

Connective Tissue Research, Cellular and Molecular Biology Letters, Arthritis Research and Therapy, Journal of Peptide Science, Expert Review of Anticancer Therapy, Cancer Chemotherapy and Pharmacology, Current Cancer Drug Targets, Mini Reviews in Medicinal Chemistry, Life Sciences, Molecular Biology Reports, International Journal of Radiation Biology, Journal of Angiogenesis Research, Journal of Biological Chemistry, Journal of Molecular and Cellular Cardiology, British Journal of Pharmacology, Expert Review in Anticancer Therapy, Chemotherapy, Journal of Cellular Biochemistry, Cancer Epidemiology, Biomarkers and Prevention, Journal of Biomedical Nanotechnology, Current Medicinal Chemistry, Basic & Clinical Pharmacology & Toxicology, Expert Opinion on Therapeutic Targets, European Journal of Medicinal Chemistry, International Immunopharmacology, British Journal of Medicine and Medical Research, Current Pharmaceutical Design, Cell Death and Disease, Plos One, British Journal of Pharmaceutical Research, Environmental Toxicology and Pharmacology, Nanomedicine: Nanotechnology, Biology, and Medicine, Science Signalling, The FEBS Journal, Oncotarget, Cytokine, Biomaterials, Scientific Reports.

- 2000-present: Member of the organizing committee of numerous national and international conferences or workshops.
- 2002-present: Reviewer of National (Hrakteitos) and International (Association for International Cancer Research, Dutch Cancer Society, Czech Science Foundation, French National Research Agency, H2020 Marie Skłodowska-Curie Action Innovative Training Networks) Research Grants.
- 2002-present: Scientific director of 5 ERASMUS bilateral agreements.
- 2005-present: Member of 8 scientific societies (Hellenic Society of Pharmacology, Greek Society of Biochemistry and Molecular Biology, Hellenic Society for Studying Bone Metabolism, American Society of Biochemistry and Molecular Biology, European Cytokine Network, European Calcified Tissue Society, American Society for Pharmacology and Experimental Therapeutics, British Society of Pharmacology).
- 2010-present: External evaluator of medicinal products for human use for the National Organization for Medicines.
- 2011-present: External evaluator of candidate post-graduate students' applications for fellowships from the State Scholarships Foundation.
- 2012- present: Member of the special interdepartmental (Chemistry, Pharmacy, Medicine) committee of the postgraduate studies program in Medicinal Chemistry: Drug Design and Development, University of Patras, Greece.
- 2014-present: Scientific Director of the postgraduate studies program of the Department of Pharmacy, School of Health Sciences, University of Patras, Greece.

ADMINISTRATIVE APPOINTMENTS AND OTHER ACTIVITIES:

- 1999-present: Member of the General Assembly and several committees of the Department of Pharmacy, University of Patras.
- 2007-2010: Treasurer of the Hellenic Society of Pharmacology.
- 2006-2007: Member of the board of the Hellenic Society of Biochemistry and Molecular Biology.
- 2010-2013: Chairman of the Committee for listing reimbursed medicinal products in Greece.
- 2011-2012: Alternate member of the Senate of the University of Patras.

2014- present: Alternate member of the Erasmus and the Erasmus+/International Credit Mobility committees of the University of Patras.

2014- present: Director of the Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras.

2016- present: Member of the Hellenic Central Board of Health (Ministry of Health).

HONORS AND AWARDS:

National Scholarship Foundation fellowship for distinction in pre-graduate studies and postgraduate fellowship as a Ph.D. student

20 prizes to participate in conferences/workshops or for best presentations

Invited speaker in 38 conferences/meetings/seminars (19 national and 19 international)

Recipient of 19 research grants (11 as a PI and 8 as collaborating group leader)

EDITORIAL BOARD MEMBER:

Recent Patents on Anti-Cancer Drug Discovery (2007-present)

The Open Cancer Journal (2008-present)

World Journal of Biological Chemistry (2010-2014)

ISRN Vascular Medicine (2011-2014)

Heliyon's (2016-present)

RESEARCH PROJECTS

Research Interests:

- Angiogenesis and tumor growth *in vivo* and *in vitro*. Pharmacological studies on the mechanisms involved, and evaluation of new compounds or nanoparticles for their anti-angiogenic and anti-tumor activity.
- The biological actions of the heparin-binding growth factor pleiotrophin. Effects on endothelial cell functions, angiogenesis, tumor growth and metastasis, bone cell biology. Signaling and receptors identification. Structure-function studies.
- The role of receptor RPTPbeta/zeta in angiogenesis and tumor growth. Structure-function studies.

Active Grants

Marie Curie Intra European Fellowship (IEF) - "Understanding tumour resistance: Receptors and signalling pathways that can lead the race against tumour angiogenesis", 2015-2017, FP7 (People), PI

Completed Grants

"Elucidation of the pleiotrophin signaling pathways that are related to endothelial cell migration", 2011-2015, Greek Ministry of Education, PI

"Development of Multi-Functional Magnetic Nanoparticles for Targeted Delivery of Anticancer Drugs", 2012-2015, Greek Ministry of Education, Collaborating group leader

Excellence for Postgraduate studies in Greece - Siemens Program, 2013-2014 PI

“Role of pleiotrophin in osteoarthritis”. Hellenic Society for studying Bone Metabolism, 2012-2013
Co-investigator

“Identification of proteins that interact with pleiotrophin and elucidation of their function”. Greek
Ministry of Education, 09/10-06/2013 PI

“Preliminary investigation of the role of the growth factor pleiotrophin as a therapeutic target for
osteoporosis by using osteoblast-like cells in vitro”. Hellenic Society for studying Bone Metabolism,
2009-2010 PI

“Structure-function studies for the growth factor pleiotrophin, in order to determine region(s) of the
molecule with anti-tumor activity”. Greek Secretariat for Research and Technology, 06/05 - 12/08 PI

“Role of pleiotrophin in the therapy of glioblastomas”. Greek Ministry of Education, 01/05 - 12/07 PI

“Mechanisms of pleiotrophin-induced cancer angiogenesis”. Empeirikion Foundation, 09/04 - 09/06
PI

“Mechanisms of action of pleiotrophin in the growth and angiogenesis of glioblastomas”. Greek
Ministry of Education, 11/02 - 03/06 PI

“Study of the role of the growth factor HARP in human prostate pathophysiology”. Greek Ministry of
Education, 11/02 - 12/05 Co-investigator

“The role of pleiotrophin in angiogenesis. Structure-function studies”. University of Patras Research
Committee, 11/02 - 10/05 PI

“Study of the role of the growth factor HARP in human prostate cancer”, Central Board of Health,
Ministry of Health, Greece, 01/01 - 12/02 Co-investigator

"Use of recombinant and synthetic peptides to define biologically active pleiotrophin peptides",
Empeirikion Foundation, 06/01 - 06/03 Co-investigator

“Study of the mechanisms through which amifostine protects chorioallantoic membrane blood vessels
from ionizing radiation”. University of Patras Research Committee, 11/00 - 10/03 Co-investigator

“Role of heat shock proteins in programmed cell death”, Greek Secretariat for Research and
Technology, 01/00 - 06/01 Co-investigator

“Study of the actions of the growth factor HARP in endothelial cells”, University of Patras Research
Committee, 10/98 - 09/01 Co-investigator

“Study of the mechanisms through which X-rays inhibit angiogenesis in order to improve their
therapeutic use in oncology”, University of Patras Research Committee, 10/98 - 09/01 PI

PUBLICATIONS

In peer reviewed journals (Scopus citations >1411, H-factor 25; Google scholar citations>2017, H-
factor: 29, <http://scholar.google.gr/citations?hl=el&user=4Fz6qhUAAAAJ&view>)

* *indicates correspondence*

1. **Karakioulakis G., Papadimitriu E.,** Missirlis E. and Maragoudakis M. E. “Effect of bivalent
metal ions on collagenase from *Clostridium histolyticum*” *Biochemistry International* 34: 397-404,
1991.

2. **Papadimitriou E.** and Lelkes P. I. “Measurement of cell numbers in microtiter culture plates
using the fluorescent dye Hoechst 33258”. *J. Immunol. Meth.* 162: 41-45, 1993.

3. **Papadimitriou E.**, Unsworth B. R., Maragoudakis M. E. and Lelkes P. I. "Time-course and quantitation of extracellular matrix maturation in the chick chorioallantoic membrane and in cultured endothelial cells". *Endothelium* 1: 207-219,1993.
4. **Papadimitriou E.**, Manolopoulos V. G., Hayman G. T., Maragoudakis M. E., Unsworth B. R., Fenton J. W. and Lelkes P. I. "Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells". *Am. J. Physiology* 272 (*Cell Physiol.*41): C1112-C1122, 1997.
5. **Papadimitriou E.**, Mintzas A., Skoutari M., Dimitracopoulos G. and Anastassiou E. D. "Cholera toxin stimulates human B-cell DR antigen biosynthesis at the level of translation". *Cellular Immunology* 180: 176-184, 1997.
6. **Papadimitriou E.**, Kritikou D., Mavroidis M., Zacharopoulou A. and Mintzas A. "The Heat Shock 70 Gene Family in the Mediterranean Fruit Fly *Ceratitis capitata*". *Insect Mol. Biol.* 7: 279-290, 1998.
7. Pipili-Synetos E., **Papadimitriou E***, and Maragoudakis M. E. "Evidence that platelets promote tube formation by endothelial cells *in vitro*". *Br. J. Pharmacol.*, 125: 1252-1257, 1998.
8. Pipili-Synetos E., Kritikou S., **Papadimitriou E.**, Athanassiadou A., Flordellis C. and Maragoudakis M. E. "Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane". *Br. J. Pharmacol.*, 129: 207-213, 2000.
9. **Papadimitriou E.** and Antimisiaris S. "Interactions of PC:Chol and PS:Chol liposomes with human cells *in vitro*: Qualitative and quantitative fluorescence studies". *J. Drug Targeting*, 8: 335-351, 2000.
10. **Papadimitriou E.**, Heroult M., Courty J., Polykratis A., Stergiou C. and Katsoris P. "Endothelial cell proliferation induced by HARP: implication of N or C terminal peptides." *Biochem. Biophys. Res. Commun.*, 274: 242-248, 2000.
11. **Papadimitriou E.**, Polykratis A., Courty J., Koolwijk P., Heroult M. and Katsoris P. "HARP induces angiogenesis *in vivo* and *in vitro*: Implication of N or C terminal peptides" *Biochem. Biophys. Res. Commun.*, 282: 306-313, 2001.
12. **Papadimitriou E.**, Maragoudakis M. E., Waters C., Manolopoulos V. G., Unsworth B. R. and Lelkes P. I. "Regulation of extracellular matrix protein deposition and MMP-2 secretion in cultured endothelial cells". *Endothelium*, 8: 243-253, 2001.
13. Giannopoulou E, Katsoris P., Hatzia Apostolou M., Kardamakis D., Kotsaki E., Polytarchou C., Parthymou A., Papaioannou, S. and **Papadimitriou E***. "X rays modulate extracellular matrix *in vivo*". *Int. J. Cancer*, 94: 690-698, 2001.
14. Kallinteri P., **Papadimitriou E.** and Antimisiaris S. "Uptake of liposomes which incorporate a glycopeptide fraction of asialofetuin by HepG2 cells", *J. Lipos. Res.*, 11: 175-193, 2001.
15. Gortzi O., **Papadimitriou E.**, Kontogiannis C.G., Antimisiaris S.G. and Ioannou P. "Arsoliposomes: a novel class of arsenic containing liposomes: Effect of palmitoyl-arsenolipid containing liposomes on the viability of cancer and normal cells in culture", *Pharm. Res.*, 19: 79-86, 2002.
16. Giannopoulou E., Katsoris P., Polytarchou C. and **Papadimitriou E***. "Nitration of cytoskeletal proteins in the chicken embryo chorioallantoic membrane". *Arch. Biochem. Biophys.*, 400: 188-198, 2002.
17. Giannopoulou E., Katsoris P., Parthymou A., Kardamakis D., and **Papadimitriou E***. "Amifostine protects blood vessels from the effects of ionizing radiation". *Anticancer Res.*, 22: 2821-2826, 2002.
18. Giannopoulou E., Katsoris P., Kardamakis D., and **Papadimitriou E***. "Amifostine inhibits angiogenesis *in vivo*". *J. Pharmacol. Exp. Ther.*, 304: 729-737, 2003.

19. Lawrence F., Liu J.-M., Kovacevic M., Bignon J., Meric P., **Papadimitriou E.**, Lallemand J.-Y., Katsoris P., Potier P., Fromes Y., and Wdzieczak-Bakala J. "The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis *in vitro* and *in vivo*". *Blood*, 101: 3014-3020, 2003.
20. Gortzi O., Antimisiaris S.G., Klepetsanis P., **Papadimitriou E.** and Ioannou P.V. "Arsonoliposomes: Effect of arsonolipid acyl chain length and vesicle composition on their toxicity towards cancer and normal cells in culture". *Eur. J. Pharm. Sci.*, 18: 175-183, 2003.
21. Hatziapostolou M., Katsoris P., and **Papadimitriou E.***. "Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis". *Eur. J. Pharmacol.*, 460: 1-8, 2003.
22. Koletsis E., Chatzimichalis A., Fotopoulos V., Kokkinis K., **Papadimitriou E.**, Tiniakos D., Marinos E., Bellenis I. and Dougenis D. "Donor lung pretreatment with surfactant in experimental transplantation preserves graft hemodynamics and alveolar morphology". *Exp. Biol. Med. (Maywood)*, 228: 540-545, 2003.
23. Giannopoulou E. and **Papadimitriou E.***. "Amifostine has antiangiogenic properties *in vitro* by changing the redox status of human endothelial cells". *Free Radical Res.*, 37: 1191-1199, 2003.
24. Heroult M., Bernard-Pierrot I., Delbe J., Hamma-Kourbali Y., Katsoris P., Barritault D., **Papadimitriou E.**, Plouet J. and Courty J. "Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis". *Oncogene*, 23: 1745-1753, 2004.
25. Polykratis A., Delbe J., Courty J., **Papadimitriou E.***. and Katsoris P. "Identification of heparin affin regulatory peptide domains with potential role on angiogenesis". *Int. J. Biochem. Cell Biol.*, 36: 1964-1976, 2004.
26. Parthymou A., Kardamakis D., Pavlopoulos G. and **Papadimitriou E.***. "Irradiated C6 glioma cells induce angiogenesis *in vivo* and activate endothelial cells *in vitro*". *Int. J. Cancer*, 110: 807-814, 2004.
27. Polytarchou C. and **Papadimitriou E.***. "Antioxidants inhibit angiogenesis *in vivo* through down-regulation of nitric oxide synthase expression and activity". *Free Radical Res.*, 38: 501-508, 2004.
28. Loutrari H., Hatziapostolou M., Skouridou V., **Papadimitriou E.**, Roussos C., Kolisis F. and Papapetropoulos A. "Perillyl alcohol inhibits angiogenesis *in vitro* and *in vivo*". *J. Pharmacol. Exp. Ther.*, 311: 568-575, 2004.
29. Polytarchou C., Gligoris T., Kardamakis D., Kotsaki E. and **Papadimitriou E.***. "X-rays affect the expression of genes involved in angiogenesis". *Anticancer Res.*, 24: 2941-2945, 2004.
30. **Papadimitriou E.***, Polykratis A., Hatziapostolou M., Parthymou A., Polytarchou C. and Mikelis C. "Heparin Affin Regulatory Peptide: A new target for tumour therapy?". *Curr Cancer Drug Targets*, 4: 471-482, 2004.
31. Arsenou E., **Papadimitriou E.**, Kliafa E., Hountala M. and Nikolaropoulos S. "Effects of retinoic acid steroidal analogues on human leukemic HL60 cells proliferation *in vitro* and on angiogenesis *in vivo*". *Anti-Cancer Drugs*, 16: 151-158, 2005.
32. Polytarchou C. and **Papadimitriou E.***. "Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity". *Eur. J. Pharmacol.*, 510: 31-38, 2005.
33. Hatziapostolou M., Delbe J., Katsoris P., Polytarchou C., Courty J. and **Papadimitriou E.***. "Heparin Affin Regulatory Peptide is a key player in prostate cancer cell growth and angiogenicity". *Prostate*, 65: 151-158, 2005.
34. Polykratis A., Katsoris P., Courty J. and **Papadimitriou E.***. "Characterization of heparin affin regulatory peptide signaling in human endothelial cells". *J. Biol. Chem.*, 280: 22454-22461, 2005.

35. Polytarchou C., Hatziapostolou M. and **Papadimitriou E***. “Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene”. *J. Biol. Chem.*, 280: 40428-40435, 2005.
36. Polytarchou C., Kardamakis D., Katsoris P and **Papadimitriou E***. “Antioxidants modify the effect of X rays on blood vessels”. *Anticancer Res.* 26: 3043-3047, 2006.
37. Kokolakis G., Mikelis C., **Papadimitriou E.**, Courty J., Karetsou E. and Katsoris P. “Effect of heparin affin regulatory peptide on the expression of vascular endothelial growth factor receptors in endothelial cells”. *In vivo* 20: 629-635, 2006.
38. Pyriohou A., Beis D., Koika V., Potytarchou C., **Papadimitriou E.**, Zhou Z. and Papapetropoulos A. “Soluble guanylyl cyclase activation promotes angiogenesis”. *J. Pharmacol. Exp. Ther.*, 319: 663-671, 2006.
39. Hatziapostolou M., Polytarchou C., Katsoris P., Courty J. and **Papadimitriou E***. “Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells”. *J. Biol. Chem.*, 281:32217-32226, 2006.
40. Gryparis E., Hatziapostolou M., **Papadimitriou E.** and Avgoustakis K. “Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells”. *Eur. J. Pharm. Biopharm.*, 67: 1-8, 2007.
41. Mikelis C., Koutsoumpa M. and **Papadimitriou E***. “Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer”. *Recent Patents on Anti-Cancer Drug Discovery*, 2: 175-186, 2007.
42. Parthymou A., Lambropoulou E., Mikelis C., Drosou G. and **Papadimitriou E***. “Heparin affin regulatory peptide/pleiotrophin interacts with vascular endothelial growth factor and negatively affects tumor growth and angiogenesis induced by glioma cells”. *Eur. J. Cell Biol.*, 87: 17-29, 2008.
43. Fousteris M.A., Vlachopoulos G., Koutsourea A., Manioudaki M., Lampropoulou E., **Papadimitriou E.**, Spyroulias G. and Nikolaropoulos S.S. “Pyrrolo[2,3-a]carbazoles as potential CDK1 inhibitors. Synthesis, preliminary evaluation and binding properties through docking simulations”. *J. Med. Chem.*, 51: 1048-1052, 2008.
44. Mikelis C. and **Papadimitriou E***. “Heparin-binding protein pleiotrophin: An important player in the angiogenic process”. *Connect. Tissue Res.*, 49: 149-152, 2008.
45. **Papadimitriou E.**, Koliakos G. and Karamanos N. “Biochemistry and Molecular Biology in Greece: History and perspectives”. *IUBMB Life* 60: 250-253, 2008.
46. Polytarchou C., Hatziapostolou M., Poimenidi E., Mikelis C., Papadopoulou A., Parthymou A. and **Papadimitriou E***. “Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase β/ζ ”. *Int. J. Cancer*, 124: 1785-1793, 2009.
47. Koutsoumpa M., Hatziapostolou M., Mikelis C., Koolwijk P., **Papadimitriou E***. “Aprotinin stimulates angiogenesis and human endothelial cell migration through through the growth factor pleiotrophin and its receptor protein tyrosine phosphatase β/ζ ”. *Eur. J. Pharmacol.*, 602: 245-249, 2009.
48. Poimenidi E., Hatziapostolou M. and **Papadimitriou E***. “Serum stimulates pleiotrophin gene expression and secretion in an AP-1 dependent manner in human endothelial and glioblastoma cells”. *Anticancer Res.*, 29: 349-354, 2009.
49. Mikelis C., Sfaelou E., Koutsoumpa M, Kieffer N. and **Papadimitriou E***. “Integrin $\alpha_v\beta_3$ is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase β/ζ ”. *FASEB J.*, 23: 1459-1469, 2009.
50. Sadikoglou E., Magoulas G., Theodoropoulou C., Athanassopoulos C., Giannopoulou E., Theodorakopoulou O., Drinias D., Papaioannou D.* and **Papadimitriou E.*** “Effect of conjugates of

all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth". *Eur. J. Med. Chem.*, 44: 3175-3187, 2009.

51. **Papadimitriou E***, Mikelis C., Lampropoulou E., Koutsoumpa M., Theochari K., Tsirmoula S., Theodoropoulou C., Lamprou M., Sfaelou E., Vourtsis D. and Mpountouris P. "Role of pleiotrophin in tumor growth and angiogenesis" *Eur. Cytokine Netw.* 20: 180-190, 2009.

52. Mattheolabakis G., Lagoumintzis G., Panagi Z., **Papadimitriou E.**, Partidos C.D. and Avgoustakis K. "Transcutaneous delivery of a nanoencapsulated antigen: Induction of immune responses". *Int. J. Pharm.*, 385: 187-193, 2010.

53. Friligou I, **Papadimitriou E.**, Gatos D., Matsoukas J. and Tselios T. "Microwave-assisted solid-phase peptide synthesis of the 60-110 domain of human pleiotrophin (hPTN) on 2-chlorotriethyl resin". *Amino Acids*, 40: 1431-1440, 2011.

54. Mikelis C., Lamprou M., Koutsoumpa M., Koutsoumbas A.G., Spyrali Z., Zompra A.A., Spiliopoulos N., Vradis A.A., Katsoris P., Spyroulias G.A., Cordopatis P., Courty J. and **Papadimitriou E.*** "A peptide corresponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro". *J. Cell. Biochem.* 112: 1532-1543, 2011.

55. Lampropoulou E., Manioudaki M., Foustieris M., Koutsourea A., Nikolaropoulos S. and **Papadimitriou E.*** "Pyrrolo[2,3- α]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo". *Biomed Pharmacother*, 65: 142-150, 2011.

56. Kouroufexi A., Theophanous-Kitiri S., Polykarpou G., Markou G. and **Papadimitriou E.** "Clinical evaluation of lenograstim use in the Bank of Cyprus Oncology Centre". *European Journal of Oncology Pharmacy (EJOP)* 5: 31-33, 2011.

57. Koutsoumpa M., Drosou G., Mikelis C., Theochari K., Vourtsis D., Katsoris P., Giannopoulou E., Courty J., Petrou C., Magafa V., Cordopatis P. and **Papadimitriou E.*** "Pleiotrophin expression and role in physiological angiogenesis in vivo: Potential involvement of nucleolin". *Vascular Cell*, 4: 4, 2012.

58. Tsirmoula S., Dimas K., HatziaPOSTOLOU M., Lamprou M., Ravazoula P and **Papadimitriou E.*** "Implication of pleiotrophin in human prostate PC3 cancer cell growth in vivo". *Cancer Sci*, 103:1826-32, 2012.

59. Pantazaka E, **Papadimitriou E***. PTN (pleiotrophin). *Atlas Genet Cytogenet Oncol Haematol* 16: 821-837, 2012.

60. Vourtsis D, Giannou T., Sadikoglou E., Theodorakopoulou O., Sarrou H., Magoulas G., Athanassopoulos CM, Drinas D., Papaioannou D. and **Papadimitriou E.*** "Effect of all-trans-retinoic acid and its conjugate with spermine on human endothelial and prostate cancer cell growth in vitro and angiogenesis in vivo". *Eur J Pharmacol*, 698: 122-130, 2013.

61. Kaspiris A, Mikelis C, Heroult M, Khaldi L, Grivas TB, Kouvaras I, Dangas S, Vasiliadis E, Lioté F, Courty J, **Papadimitriou E.*** "Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in the serum, cartilage and subchondral bone of patients with osteoarthritis". *Joint Bone Spine*, 80: 407-413, 2013.

62. Koutsoumpa M., Polytarchou C., Courty J., Zhang Y., Kieffer N., Mikelis C., Skandalis S., Hellman U., Iliopoulos D. and **Papadimitriou E.*** "Interplay between α v β 3 integrin and nucleolin regulates human endothelial and glioma cell migration". *J Biol. Chem.*, 288: 343-354, 2013.

63. Kaspiris A., Khaldi L., Grivas T.B., Vasiliadis E., Kouvaras I., Dagkas S., Chronopoulos E. and **Papadimitriou E.** "Subchondral cyst development and MMP-1 expression during progression of osteoarthritis: an immunohistochemical study". *Orthop Traumatol Surg Res*, 99: 523-529, 2013.

64. Koniari I., Apostolakis E., Diamantopoulos A., Papadaki H., **Papadimitriou E.**, Poimenidi E., Karnabatidis D., Karahaliou A., Costaridou L., Papalois A., Siablis D., Dougenis D., Alexopoulos D.

Transaortic balloon angioplasty in rabbit thoracic aorta: a novel model of experimental restenosis. *Lipids Health Dis.* 13: 33, 2014.

65. Koutsoumpa M. and **Papadimitriou E***. “Cell surface nucleolin as a target for anti-cancer therapies”. *Recent Pat Anticancer Drug Discov*: 9: 137-152, 2014.

66. Pantazaka E. and **Papadimitriou E***. “Chondroitin Sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration”. *BBA - General Subjects*, 1840: 2643-2650, 2014.

67. Vasiliadis E.S., Kaspiris A., Grivas T.B., Khaldi L., Lamprou M., Pneumaticos S.G., Nikolopoulos K., Korres D.S., **Papadimitriou E.** “Expression of macrophage elastase (MMP12) in rat tail intervertebral disc and growth plate during degeneration after asymmetric loading”. *Bone Joint Res* 3: 273-279, 2014.

68. Lamprou M., Kaspiris A., Panagiotopoulos E., Giannoudis P., **Papadimitriou E.*** “The role of pleiotrophin in bone repair”. *Injury* 45: 1816-1823, 2014.

69. Koutsoumpa M., Poimenidi E., Pantazaka E., Theodoropoulou C., Skoura A., Megalioikonomou V., Kieffer N., Courty J., Mizumoto S., Sugahara K. and **Papadimitriou E.*** “Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor”. *Mol Cancer*, 14: 19, 2015.

70. Tsirmoula S., Lamprou M., Hatziapostolou M., Kieffer N. and **Papadimitriou E.*** “Pleiotrophin-induced endothelial cell migration is regulated by xanthine oxidase-mediated generation of reactive oxygen species”. *Microvasc Res*, 98:74-81, 2015.

71. Kaspiris A., Khaldi L., Chronopoulos E., Vasiliadis E., Grivas T., Kouvaras I., Dagkas S. and **Papadimitriou E.** “Macrophage - specific metalloelastase (MMP - 12) immunoexpression in the osteochondral unit in osteoarthritis correlates with BMI and disease severity”. *Pathophysiology*, 22: 143-151, 2015.

72. Koniari I., Mavrilas D., Papadaki H., **Papadimitriou E.**, Poimenidi E., Papalois A., Hahalis G., Xanthopoulou I., Alexopoulos D., Apostolakis E. “Simvastatin and ivabradine inhibiting atherosclerosis progression, intimal hyperplasia and peroxynitrite-mediated oxidative stress reduce thoracic aorta's stiffness in hypercholesterolemic rabbits”. *J Cardiovasc Pharmacol Ther*, doi: 10.1177/1074248415617289, 2015.

73. Giannopoulou E., Nikolakopoulos A., Kotsirilou D., Lampropoulou A., Raftopoulou S., **Papadimitriou E.**, Theocharis A.D., Makatsoris T., Fasseas K. and Kalofonos H.P. “Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells”. *J Biomed Sci*, 22: 98, 2015.

74. Kaspiris A., Chronopoulos E., Grivas T.B., Vasiliadis E., Khaldi L., Lamprou M., Lelovas P.P., Papaioannou N., Dontas I.A., **Papadimitriou E.*** “Effects of mechanical loading on the expression of pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in a rat spinal deformity model”. *Cytokine*, 78:7-15, 2016.

75. Poimenidi E., Theodoropoulou C., Koutsoumpa M., Skondra L., Droggiti E., van den Broek M., Koolwijk P., **Papadimitriou E.*** “Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner”. *Vasc Pharmacol*, doi: 10.1016/j.vph.2016.02.008, 2016.

76. Sarigiannis Y., Kolokithas-Ntoukas A., Beziere N., Ntziachristos V., Radek Z., **Papadimitriou E.**, Avgoustakis K., Lamprou M., Markova Z., Rousalis E. and Bakandritsos A. “Synthesis and Evaluation of Condensed Magnetic Nanocrystal Clusters with in vivo Multispectral Optoacoustic Tomography for Tumour Targeting Biomaterials”. *Biomaterials*, accepted, 2016.

77. Tsigkas G., Katsanos K., Apostolakis E., **Papadimitriou E.**, Koutsoumpa M., Karnabatidis D., Kagadis G.C., Koumoundourou D., Hahalis G. and Alexopoulos D. “A novel endovascular experimental model for induction of chronic myocardial hypertrophy in rabbits”. *Submitted*.

78. **Papadimitriou E.***, Castana P., Tsalios T. and Pantazaka E. “Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as angiogenesis regulators”. *Expert Opinion on Therapeutic Targets*, submitted, 2015.
79. Panagi Z., Bountouris P., Skroubis G., **Papadimitriou E.**, Skouroliakou M., Kalfarentzos F. “Fat soluble vitamin serum levels in obese patients under supplementation after Roux-en-Y gastric bypass/biliopancreatic diversion”. *In preparation*.
80. Theodorakopoulou O., Tsirmoula S., Hatziapostolou M. and **Papadimitriou E.*** “Role of pleiotrophin in the inhibitory effect of all trans retinoic acid on human prostate cancer cell migration”. *In preparation*.
81. Lampropoulou E., Parthymou A., Lamprou M. and **Papadimitriou E.*** “cAMP up-regulates PTN expression through protein kinase A and activator protein-1”. *In preparation*.
82. Lampropoulou E., Logoviti I., Hatziapostolou M., Koutsoumpa M., Skandalis S., Tsihchlis P.N., Hellman U. and **Papadimitriou E.*** “Cyclin-dependent kinase 5 is involved in pleiotrophin-induced endothelial cell migration”. *In preparation*.

Invited chapters in books

1. Polytarchou C., Hatziapostolou M. and **Papadimitriou E.** “Endothelial cell migration assays”. In: “Angiogenesis assays: A critical appraisal of current techniques”, Editors: Carolyn Staton, Claire Lewis and Roy Bicknell, John Wiley and Sons, Ltd, 2006, pages 51-64.
2. Polytarchou C., Hatziapostolou M., Poimenidi E. and **Papadimitriou E.** “Reactive oxygen species as mediators of angiogenesis signalling”. In: “Angiogenesis: Basic Science and Clinical Applications”, Editors: Michael E. Maragoudakis and Evangelia Papadimitriou, Transworld Research Network, 2007, pages 213-233.
3. **Papadimitriou E.** “Pleiotrophin”. In: “Encyclopedia of Cancer” 2nd Edition, pages 2367-2369. Editor: Manfred Schwab, Springer-Verlag, 2008.
4. Koutsoumpa M. and **Papadimitriou E.** “PG receptors with phosphatase action in cancer and angiogenesis”. In: “Extracellular Matrix: Pathobiology and Signalling”, Editor: Nikos Karamanos, Walter de Gruyter GmbH & Co. KG, Berlin/Boston, 2012, pages 813-823.
5. **Papadimitriou E.** “Pleiotrophin”. In: “Encyclopedia of Cancer”, doi: 10.1007/978-3-642-27841-9_4621-3. Editor: Manfred Schwab, Springer-Verlag Berlin Heidelberg, 2014.
6. Koutsoumpa M., Choleva E., **Papadimitriou E.** "Targeting Cell Surface Nucleolin in Cancer". In: Patent eBook Series "Topics in Anti-Cancer Research", Volume 4, Editors: Atta-ur-Rahman, Khurshid Zaman, Bentham eBooks, 2015, pages 104-155.

Publications in greek journals

1. Tziafeta S.G., Karamelas N.A., Skotsimara P., Korfiati E., **Papadimitriou E.** and Skeparni F. “Toxicological aspects of sudden and violent deaths in Southwestern Greece: A three-year review (2001-2004)”. *Hellenic Medical and Pharmaceutical Review* II(2): 33-43, 2005.
2. Karamelas N.A., Tziafeta S.G., Skotsimara P., Korfiati E., **Papadimitriou E.** and Skeparni F. “Toxicological aspects of fatal accidents in Southwestern Greece: A three-year experience (2001-2004)”. *Hellenic Medical and Pharmaceutical Review* II(2): 44-53, 2005.
3. Vomvas D., Mpountouris P., Theodoropoulou X., Dermizioti E., Viha A., **Papadimitriou E.**, and Kardamakis D. “Neutrophils growth factors and radiotherapy”. *Forum of Clinical Oncology* 8 (3-4):175-183, 2009.

4. Lamprou M., Koutsoumpa M., Kaspiris A., Vasiliadis E., Kataxaki E. and **Papadimitriou E***. "The role of pleiotrophin and its receptor RPTP β/ζ in bone pathophysiology." *Ostoun* 22 (4): 188-198, 2011.
5. Chronopoulos E. , Kaspiris A., Khaldi L., Vasiliadis E., Kataxaki E., Papaioannoy N. and **Papadimitriou E.** " Monosodium Iodoacetate (MIA) induced experimental osteoarthritis animal model". *Ostoun* 25(1): 6-13, 2014.

Publications in conference proceedings

1. **Papadimitriou E.**, Unsworth B. R., Maragoudakis M. E. and Lelkes P. I. "Quantitative analysis of extracellular matrix formation *in vivo* and *in vitro*". *In: Angiogenesis: Molecular Biology, Clinical Aspects*, ed. by Maragoudakis, M.E., Gullino, P.M., Lelkes, P.I., Plenum Press, *pps.* 291-305, 1994.
2. **Papadimitriou E.**, Unsworth B. R., Maragoudakis M. E. and Lelkes P. I. "Expression of SPARC during embryonic development of the chick chorioallantoic membrane". *In: Angiogenesis: Molecular Biology, Clinical Aspects*, ed. by Maragoudakis, M.E., Gullino, P.M., Lelkes, P.I., Plenum Press, page 354, 1994.
3. **Papadimitriou E.**, Maragoudakis M. E., Manolopoulos V. G., Unsworth B. R., and Lelkes P. I. "Differential regulation of extracellular matrix protein secretion and deposition by cultured endothelial cells". *In: Molecular, Cellular and Clinical aspects of Angiogenesis*, ed. by Maragoudakis, M.E., Plenum Press, page 274, 1996.
4. Papaioannou S., Hatjimichael H., **Papadimitriou E.**, Kardamakis D. and Demopoulos J. Effects of X-ray irradiation doses and NO synthase modulation on embryonic angiogenesis. *In: Vascular Endothelium: Mechanisms of Cell Singnaling*, ed. by Catravas, J., Callow, A. and Ryan, U., IOS Press, *pps.* 206-208, 1999.
5. Katsoris P., Courty J., Polykratis A., Giannopoulou E., Papaioannou S. and **Papadimitriou E.** "HARP and endothelium". *In: Vascular Endothelium: Source and Target of Inflammatory Mediators*, ed. by Catravas, J., Callow, A. and Ryan, U., IOS Press, *pps.* 313-315, 2001.
6. **Papadimitriou E.**, Giannopoulou E., Katsoris P., Hatziapostolou M., Kardamakis D. and Papaioannou, S. "Protective implication of andioxidants in the chick embryo chorioallantoic membrane". *In: Vascular Endothelium: Source and Target of Inflammatory Mediators*, ed. by Catravas, J., Callow, A. and Ryan, U., IOS Press, *pps.* 332-334, 2001.
7. Polycratis A., **Papadimitriou E.**, Courty J., Stergiou C., Papaioannou S. and Katsoris P. "Biological action of peptides derived from the molecule of the growth factor HARP". *In: 2nd Hellenic Forum of Bioactive Peptides*, ed. by Cordopatis P.A., Typorama, *pps.* 467-473, 2001.
8. **Papadimitriou E.**, Polykratis A., Karetsoy E., Courty J. And Katsoris P. "Use of synthetic peptides for the identification of the biologically active domains of the growth factor HARP". *In: Drug Discovery and Design: Medical Aspects*, ed. by Matsoukas, J. and Mavromoustakos T., IOS Press, *pps.* 251-257, 2002.
9. Polykratis A., **Papadimitriou E.**, Mikelis C., Zompra A., Galanis A., Cordopatis P., Courty J. and Katsoris P. "Synthesis and biological action of two synthetic peptides corresponding to the C-terminal region of HARP" *In: 3rd Hellenic Forum of Bioactive Peptides*, ed. by Cordopatis P.A., Manesi-Zoupa E. and Pairas G., Typorama, *pps.* 473-480, 2003.

Cited conference presentations

1. **Papadimitriou E.**, Unsworth B. R., Maragoudakis M. E. and Lelkes P. I. "Quantitative analysis of extracellular matrix formation *in vivo* and *in vitro*". *32nd Annual Meeting of the American Society for Cell Biology*, Denver, Colorado, USA, December 15-19, 1992. Mol. Biol. Cell. 3 (Suppl.): 228a, 1992.

2. **Papadimitriou E.**, Unsworth B. R., Maragoudakis M. E. and Lelkes P. I. "Quantitative analysis of SPARC during embryonic development of the chick chorioallantoic membrane". *FASEB Experimental Biology '93*, New Orleans, Louisiana, USA, March 28-April 1, 1993. FASEB J. 7: A126, 1993.
3. **Papadimitriou E.**, Unsworth B. R., Maragoudakis M. E. and Lelkes P. I. "Thrombin increases extracellular matrix deposition in cultured endothelial cells by a mechanism independent of its proteolytic activity". *33rd Annual Meeting of the American Society for Cell Biology*, New Orleans, Louisiana, USA, December 11-15, 1993. Mol. Biol. Cell. Suppl. 4: 1033a, 1993.
4. **Papadimitriou E.**, Mintzas A., Skoutari M., Dimitracopoulos G. and Anastassiou E. D. "Cholera toxin stimulates human B-cell DR antigen biosynthesis at the level of translation". *8th European Congress of Clinical Microbiology and Infectious Diseases*, Lausanne, Switzerland, May 25-28, 1997. J. Clin. Microbiol. Infec. 3 (Suppl. 2): 201, 1997.
5. **Papadimitriou E.** and Antimisariaris S. "Interactions of PC:chol liposomes with human cells *in vitro*: qualitative and quantitative fluorescence studies" *The 6th liposome research days conference*, Les Embiez, France, May 28-31, 1998. J. Lipos. Res. 8: 93-94, 1998.
6. Giannopoulou Å., Kardamakis D., Katsoris P., Papaioannou S. and **Papadimitriou E.** "Amifostine inhibits the antiangiogenic action of X rays" *1st Panhellenic Congress of Pharmacology*, Athens, Greece, February 19-20, 1999. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 13: 78, 1999.
7. Giannopoulou E., Kardamakis D., Katsoris P., Papaioannou S. and **Papadimitriou E.** "Amifostine inhibits the antiangiogenic action of X rays". *19th Annual Estro Meeting*, Istanbul, Turkey, September 19-23, 2000. Radioth. Oncol. 56 (Suppl. 1), p. S183, 2000.
8. Polycratis A., Heroult M., **Papadimitriou E.**, Courty J. and Katsoris P. "Angiostatic activity of HARP peptide generated by plasmin treatment". *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. Anticancer Res. 21 (3A), p.1653, 2001.
9. Giannopoulou E., Katsoris P., Hatziapostolou M., Kardamakis D., Kotsaki E., Polytarchou C., Parthymou A., Papaioannou, S. and **Papadimitriou E.** "X-Rays modulate synthesis and degradation of extracellular matrix proteins". *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. Anticancer Res. 21 (3A), p.1634, 2001.
10. Polytarchou C., Katsoris P., Kardamakis D. and **Papadimitriou E.** "Free radical scavengers alter the anti- angiogenic effect of x rays". *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. Anticancer Res. 21 (3A), p.1654, 2001.
11. Hatziapostolou M., **Papadimitriou E.**, Giannopoulou E., Koolwijk P. and Katsoris P. "Inhibition of plasmin stimulates angiogenesis *in vivo*". *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. Anticancer Res. 21 (3A), p.1636, 2001.
12. Parthymou A., Katsoris P., Kardamakis D. and **Papadimitriou E.** "Induction of angiogenesis and tumour progression by irradiated C6 glioma cells on the chick chorioallantoic membrane". *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. Anticancer Res. 21 (3A), p.1651, 2001.
13. **Papadimitriou E.**, Polycratis A., Heroult M., Kokolakis G., Courty J. and Katsoris P. "HARP is an angiogenic growth factor". *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. Anticancer Res. 21 (3A), p.1653, 2001.

14. Parthymou A., Katsoris P., Kardamakis D., and **Papadimitriou E.** "Induction of angiogenesis and tumour progression by irradiated C6 glioma cells implanted on the chicken embryo chorioallantoic membrane". *ECCO 11 European Cancer Conference*, Lisbon, Portugal, October 21-25, 2001. Eur. J. Cancer, Vol. 37 (Suppl. 6), p. S112, 2001.
15. Giannopoulou E., Katsoris P., Hatziapostolou M., Kardamakis D., Kotsaki E., Polytarchou C., Parthymou A., Papaioannou, S. and **Papadimitriou E.** "X Rays affect the extracellular matrix in a way that favours both normal and tumour-induced angiogenesis". *ECCO 11th European Cancer Conference*, Lisbon, Portugal, October 21-25, 2001. Eur. J. Cancer, Vol. 37 (Suppl. 6), p. 111, 2001.
16. **Papadimitriou E.**, Polycratis A., Heroult M., Kokolakis G., Courty J. and Katsoris P. "The angiogenic role of HARP, a novel growth factor". *ECCO 11 European Cancer Conference*, Lisbon, Portugal, October 21-25, 2001. Eur. J. Cancer, Vol. 37 (Suppl. 6), p. 111, 2001.
17. Giannopoulou E., Katsoris P., Parthymou A., Kardamakis D., and **Papadimitriou E.** "Amifostine protects blood vessels from the effects of X rays and prevents radiation-induced tumor growth and angiogenesis". *2nd Panhellenic Congress of Pharmacology*, Athens, Greece, February 9-10, 2002. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 16: 41, 2002.
18. **Papadimitriou E.**, Kokolakis G., Courty J., Heroult M. and Katsoris P. "Contribution of the growth factor HARP in angiogenesis" *3rd Conference on Drug Discovery and Design*, Patras, Greece, March 7-9, 2002. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 17: 67, 2003.
19. Kliafa E., Katsoris P., Arsenou E., Nikolaropoulos S. and **Papadimitriou E.** "Effect of retinoic acid and its analogues on tumor growth and angiogenesis" *3rd Conference on Drug Discovery and Design*, Patras, Greece, March 7-9, 2002. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 17: 102, 2003.
20. Sideris S., Katsoris P. and **Papadimitriou E.** "HARP, nitric oxide and tumor growth" *3rd Conference on Drug Discovery and Design*, Patras, Greece, March 7-9, 2002. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 17: 106, 2003.
21. **Papadimitriou E.**, Polytarchou C., Gligoris T., Kardamakis D. and Katsoris P. "X rays affect the expression of several genes in a way that favors angiogenesis". *21st Annual ESTRO Meeting*, Prague, Czech Republic, September 17-21, 2002. Radioth. Oncol. 64 (Suppl. 1), p. S190, 2002.
22. Giannopoulou E., Katsoris P., Parthymou A., Kardamakis D. and **Papadimitriou E.** "Amifostine prevents radiation-induced tumor growth". *21st Annual ESTRO Meeting*, Prague, Czech Republic, September 17-21, 2002. Radioth. Oncol. 64 (Suppl. 1), p. S190, 2002.
23. Polykratis A., Mikelis C., Katsoris P., Courty J., Zompra A., Cordopatis P. and **Papadimitriou E.** "HARP domains with different activity on angiogenesis". *4th Conference on Drug Design and Development*, Patras, Greece, March 13-14, 2003. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 17: 85, 2003.
24. Parthymou A., Giannopoulou E., Polytarchou C., Hatziapostolou M., Katsoris P., Kardamakis D. and **Papadimitriou E.** "Induction of angiogenesis by irradiation". *2nd International Conference on Translational Research and Preclinical Strategies in Radiation Oncology*, Lugano, Switzerland, March 16-19, 2003. Int. J. Rad. Oncol. Biol. Phys. 55: 504, 2003.
25. Polykratis A., **Papadimitriou E.**, Courty J. and Katsoris P. "Identification of HARP domains with potential activity on angiogenesis *in vitro*". *11th Panhellenic Pharmaceutical Congress*, Athens, Greece, March 29-31, 2003. Eur. J. Drug Metab. Pharmacokinet. 28: 22, 2003.
26. Giannopoulou E. and **Papadimitriou E.** "Effect of amifostine on angiogenesis". *11th Panhellenic Pharmaceutical Congress*, Athens, Greece, March 29-31, 2003. Eur. J. Drug Metab. Pharmacokinet. 28: 22, 2003.
27. Giannopoulou E. and **Papadimitriou E.** "Amifostine and endothelial cell functions". *SFRR-Europe Meeting 2003 "Free Radicals and Oxidative Stress: Chemistry, Biochemistry and*

Pathophysiological Implications”, Ioannina, Greece, June 26-29, 2003. Free Radical Res. 37: 92, 2003.

28. Liu J.M., Bignon J.S., Lawrence F., Meric P., Kovacevic M., **Papadimitriou E.**, Katsoris P., Fromes Y. and Wdzieczak-Bakala J. “The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, controls normal and pathological angiogenesis”. *32nd Annual Meeting, International Society for Experimental Hematology*, Paris, France, July 5-8, 2003. Exp. Hematol. 31: 215, 2003.

29. Polykratis A., **Papadimitriou E.**, Delbe J., Courty J. and Katsoris P. “HARP peptides modulate the *in vitro* angiogenic activity of VEGF”. *ECCO 12 - The European Cancer Conference*, Copenhagen, Denmark, September 21-25, 2003. Eur. J. Cancer Suppl 1 (5): S178, 2003.

30. Giannopoulou E., Kardamakis D. and **Papadimitriou E.** “Amifostine modulates endothelial cell proliferation and migration”. *ECCO 12 - The European Cancer Conference*, Copenhagen, Denmark, September 21-25, 2003. Eur. J. Cancer Suppl 1 (5): S178, 2003.

31. Hountala M., Arsenou E., Nikolaropoulos S., Hatzia Apostolou M. and **Papadimitriou E.** “Effect of retinoic acid analogue on tumor growth and angiogenesis”. *ECCO 12 - The European Cancer Conference*, Copenhagen, Denmark, September 21-25, 2003. Eur. J. Cancer Suppl 1 (5): S298, 2003.

32. Polytarchou C. and **Papadimitriou E.** “Reactive oxygen species are implicated in physiological angiogenesis *in vivo* and *in vitro*”. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 18: 28-29, 2004.

33. Hatzia Apostolou M. and **Papadimitriou E.** “Effect of HARP on the growth of human prostate cancer cells”. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 18: 121-122, 2004.

34. Karampelas NA, Tziafeta SG, **Papadimitriou E.** and Skeparni F. “Toxicological aspects of fatal accidents in south-western Greece: A three-year experience (2001-2003)”. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 18: 126-127, 2004.

35. Mikelis C., Polykratis A., Zompra A., Cordopatis P., Katsoris P., Courty J. and **Papadimitriou E.** “A synthetic peptide that corresponds to the C-terminal region of HARP inhibits angiogenesis *in vivo* and *in vitro*”. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 18: 144-145, 2004.

36. Parthymou A., Kardamakis D. and **Papadimitriou E.** “Irradiation of C6 glioma cells with X rays increases the expression of angiogenic genes and their angiogenic potential *in vitro* and *in vivo*”. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 18: 165-166, 2004.

37. Tziafeta SG, Karampelas NA, **Papadimitriou E.** and Skeparni F. “Toxicological aspects of sudden and violent deaths in southwestern Greece: A three year review (2001-2003)”. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 18: 184-185, 2004.

38. Mikelis C., Polykratis A., Katsoris P., Zompra A., Cordopatis P., Courty J. and **Papadimitriou E.** “Antiangiogenic activity of a synthetic peptide that corresponds to the C-terminal region of HARP”. *4th Hellenic Forum on Bioactive peptides*, Patras, Greece, April 22-24, 2004. J Peptide Sci Suppl 10: H62, 2004.

39. Polykratis A., **Papadimitriou E.**, Delbe J., Courty J. and Katsoris P. “Plasmin generates biologically active peptides of the growth factor HARP”. *4th Hellenic Forum on Bioactive peptides*, Patras, Greece, April 22-24, 2004. J Peptide Sci Suppl 10: H71, 2004.

40. Parthymou A., Kardamakis D. and **Papadimitriou E.** “Irradiation of C6 glioma cells with X rays increases the expression of angiogenic genes and their angiogenic potential *in vitro* and *in vivo*”. *23rd*

Annual ESTRO Meeting, Amsterdam, The Netherlands, October 24-28, 2004. Radioth. Oncol. 73 (Suppl. 1), p. S152, 2004.

41. Giannopoulou E., Hatziapostolou M., Kardamakis D. and **Papadimitriou E.** “The effect of X rays on synthesis and deposition of ECM proteins *in vivo*”. *23rd Annual ESTRO Meeting*, Amsterdam, The Netherlands, October 24-28, 2004. Radioth. Oncol. 73 (Suppl. 1), p. S190, 2004.

42. Parthymou A. and **Papadimitriou E.** “Role of HARP on the growth of glioblastoma cells””. *6th Conference on Drug Design and Development*, Patras, Greece, March 10-12, 2005. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 380, 2006.

43. Polykratis A., Mikelis C., Katsoris P., Courty J. and **Papadimitriou E.** “Heparin affin regulatory peptide signaling in human endothelial cells”. *ECCO 13 -The European Cancer Conference*, Paris, France, October 30 - November 3, 2005. Eur. J. Cancer Suppl 3 (2): 54, 2005.

44. Theodorakopoulou O., Hatziapostolou M., Polytarchou C., Delbe J., Courty J. and **Papadimitriou E.** “Effect of retinoic acid on prostate cancer cells *in vitro*”. *ECCO 13 - The European Cancer Conference*, Paris, France, October30 - November 3, 2005. Eur. J. Cancer Suppl 3 (2): 55, 2005.

45. Parthymou A. and **Papadimitriou E.** “Tumor growth and angiogenesis induced by C6 glioma cells are regulated by heparin affin regulatory peptide *in vivo* and *in vitro*”. *ECCO 13 - The European Cancer Conference*, Paris, France, October 30 - November 3, 2005. Eur. J. Cancer Suppl 3 (2): 59, 2005.

46. Lampropoulou E., Parthymou A. and **Papadimitriou E.** “Regulation of heparin affin regulatory peptide expression by cAMP in glioma cells”. *7th Conference on Drug Design and Development*, Patras, Greece, March 8-11, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 21: 141, 2007.

47. Hatziapostolou M., Polytarchou C. and **Papadimitriou E.** “FGF-2 incites biological activities of human prostate cancer cells via hydrogen peroxide-dependent activation of HARP/pleiotrophin gene”. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 97, 2006.

48. Drosou G. and **Papadimitriou E.** “Expression of heparin affin regulatory peptide is essential for angiogenesis *in vivo*”. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 155, 2006.

49. Lambropoulou E., Parthymou A. and **Papadimitriou E.** “The role of cAMP in heparin affin regulatory peptide expression in glioma cells”. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 241, 2006.

50. Mikelis C., Zompra A., Cordopatis P. and **Papadimitriou E.** “A synthetic peptide that corresponds to the C-terminal region of HARP inhibits effects of HARP on endothelial cells”. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 254, 2006.

51. Poimenidi E., Polykratis A. and **Papadimitriou E.** “Serum regulates the expression of heparin affin regulatory peptide”. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 301, 2006.

52. Theodorakopoulou O. and **Papadimitriou E.** “Effect of all-trans retinoic acid on prostate cancer cell growth”. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 20: 331, 2006.

53. Theodorakopoulou O., Hatziapostolou M. and **Papadimitriou E.** “ATRA’s inhibitory effect on prostate cancer cell growth involves HARP expression”. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. The FEBS Journal, 273 (Suppl. 1): 86, 2006.

54. Lampropoulou E., Parthymou A., Poimenidi E., Giannopoulou E. and **Papadimitriou E.** “Expression of heparin affin regulatory peptide in glioma cells”. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. The FEBS Journal, 273 (Suppl. 1): 122, 2006.
55. Polytarchou C., Hatziapostolou M. and **Papadimitriou E.** “On the interventional role of eNOS in hydrogen peroxide-induced HARP/pleiotrophin up-regulation in endothelial cells”. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. The FEBS Journal, 273 (Suppl. 1): 149, 2006.
56. Hatziapostolou M., Polytarchou C. and **Papadimitriou E.** “FGF-2 stimulatory effects on human prostate cancer cells are mediated by HARP/pleiotrophin: Implication of hydrogen peroxide”. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. The FEBS Journal, 273 (Suppl. 1): 223, 2006.
57. Polytarchou C., Hatziapostolou M., Papadopoulou A., Poimenidi E. and **Papadimitriou E.** “Hydrogen peroxide stimulatory effects on endothelial cells are mediated by heparin affin regulatory peptide: Implication of endothelial nitric oxide synthase”. *8th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Corfu, Greece, June 29 - July 3, 2006. Endothelium, 13: 296, 2006.
58. Parthymou A., Lampropoulou E., Mikelis C., Drosou G. and **Papadimitriou E.** “Role of heparin affin regulatory peptide in glioma cell growth and angiogenicity”. *8th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Corfu, Greece, June 29 - July 3, 2006. Endothelium, 13: 297, 2006.
59. Hatziapostolou M., Polytarchou C. and **Papadimitriou E.** “FGF-2 stimulates LNCaP cell functions through heparin affin regulatory peptide up-regulation”. *8th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Corfu, Greece, June 29 - July 3, 2006. Endothelium, 13: 309, 2006.
60. Drosou G., Mikelis C. and **Papadimitriou E.** “Role of heparin affin regulatory peptide in angiogenesis *in vivo*”. *8th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Corfu, Greece, June 29 - July 3, 2006. Endothelium, 13: 311, 2006.
61. Poimenidi E., Hatziapostolou M. and **Papadimitriou E.** “Regulation of the expression of heparin affin regulatory peptide by serum in human endothelial and glioma cells”. *8th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Corfu, Greece, June 29 - July 3, 2006. Endothelium, 13: 311, 2006.
62. Lampropoulou E., Lambrou M., Parthymou A., Koutsoumpa M., Mikelis C., Giannopoulou E. and **Papadimitriou E.** “Pleiotrophin as a new target for therapy of tumors”. *32nd FEBS Congress*, Vienna, Austria, July 7-12, 2007. The FEBS Journal, 274 (Suppl. 1): 160, 2007.
63. Panagi Z., Bountouris P., **Papadimitriou E.**, Skouroliakou M., Kalfarentzos F. “Preliminary evaluation of preoperative and short-term (1 year) postoperative serum fat-soluble vitamin levels in super-obese patients undergoing a Roux-en-Y gastric bypass with biliopancreatic diversion (RYGBP/BPD) malabsortive operation”. *5th Panhellenic Congress of Pharmacology*, Athens, Greece, May 23-25, 2008. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 22: 264, 2008.
64. Koutsoumpa M., Hatziapostolou M., Mikelis C. and Papadimitriou E. “The stimulatory effects of aprotinin on human endothelial and prostate cancer cells are mediated by pleiotrophin”. *5th Panhellenic Congress of Pharmacology*, Athens, Greece, May 23-25, 2008. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 22: 201-202, 2008.
65. Mikelis C. and **Papadimitriou E.** “Novel mechanism that mediates the angiogenic properties of pleiotrophin through $\alpha_v\beta_3$ ”. *33rd FEBS Congress and 11th IUBMB Conference*, Athens, Greece, June 28-July 3, 2008. The FEBS Journal, 275 (Suppl. 1): 314, 2008.
66. Drosou G., Mikelis C., Theochari K., Vourtsis D., Giannopoulou E., Katsoris P. and **Papadimitriou E.** “Expression of pleiotrophin is essential for angiogenesis *in vivo*”. *33rd FEBS Congress and 11th IUBMB Conference*, Athens, Greece, June 28-July 3, 2008. The FEBS Journal, 275 (Suppl. 1): 317, 2008.

67. Tsirmoula S. and **Papadimitriou E.** “Reactive oxygen species mediate the stimulatory effect of pleiotrophin on human cell migration”. *33rd FEBS Congress and 11th IUBMB Conference*, Athens, Greece, June 28-July 3, 2008. The FEBS Journal, 275 (Suppl. 1): 321, 2008.
68. **Papadimitriou E.**, Mikelis C., Lampropoulou E., Koutsioumpa M., Theochari K., Tsirmoula S., Theodoropoulou C., Lamprou M., Sfaelou E., Vourstsi D. and Mpountouris P. “The role of the growth factor pleiotrophin and its receptors in tumor growth and angiogenesis”. *8th International Conference of Anticancer Research*, Kos, Greece, October 17-22, 2008. Anticancer Res. 28 (5C): 3436, 2008.
69. Daletos G., Magafa V., Panagoulis A., Lamprou M., **Papadimitriou E.**, Geronikaki A. and Cordopatis P. “Synthesis and biological evaluation of cyclic peptides of $\alpha_4\beta_1$ integrin antagonists”. *14th Panhellenic Pharmaceutical Congress*, Athens, Greece, May 9-11, 2009. European Journal of Drug Metabolism and Pharmacokinetics 34 special issue: 21-22, 2009.
70. Koutsioumpa M. and **Papadimitriou E.** “A role of nucleolin in the pleiotrophin-induced cell migration”. *34th FEBS Congress*, Prague, Czech Republic, July 4-9, 2009. The FEBS Journal, 276 (Suppl. 1): 240, 2009.
71. Tsirmoula S. and **Papadimitriou E.** “Pleiotrophin increases intracellular ROS levels and cell migration through activation of $\alpha_v\beta_3$ integrin”. *34th FEBS Congress*, Prague, Czech Republic, July 4-9, 2009. The FEBS Journal, 276 (Suppl. 1): 254, 2009.
72. Cordopatis P., Daletos G., Magafa V., Lamprou M., **Papadimitriou E.**, Zoumpoulakis P., Zervou M., Assimomytis N., Geronikaki A. Synthesis, “Evaluation and conformational solution studies of cysteine-based $\alpha_4\beta_1$ integrin ligands”. *7th Hellenic Forum on Bioactive Peptides*, Patras, Greece, May 16-17, 2010. Journal of Peptide Science 16 (Issue S2): 159, 2010.
73. Theodoropoulou C. and **Papadimitriou E.** “Role of pleiotrophin and its receptor protein tyrosine phosphatase β/ζ in vascular endothelial growth factor-induced endothelial cell migration”. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 24: 141, 2010.
74. Koutsioumpa M., Mikelis C., Kieffer N., Skandalis S., Hellman U., Petrou C., Magafa V., Cordopatis P. and **Papadimitriou E.** “Cell surface expression of nucleolin is maintained by $\alpha_v\beta_3$ integrin and is required for pleiotrophin-induced cell migration”. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 24: 161, 2010.
75. Lampropoulou E., Hatzia Apostolou M., Skandalis S., Tsihchlis P.N., Hellman U. and **Papadimitriou E.** “Cyclin-dependent kinase 5 interacts with RPTP β/ζ and mediates pleiotrophin-induced endothelial cell migration”. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 24: 165, 2010.
76. Tsirmoula S., Dimas K., Ravazoula P and **Papadimitriou E.** “Role of pleiotrophin in human prostate cancer cell growth in vivo”. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 24: 217, 2010.
77. Vourstsi D., Sadikoglou E., Theodorakopoulou O., Lampropoulou C., Magoulas G., Drinas D., Papaioannou D. and Papadimitriou E. “Effect of all-trans-retinoic acid and conjugate with spermine on human endothelial and prostate cancer cell growth in vitro and angiogenesis in vivo”. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. Review of Clinical Pharmacology and Pharmacokinetics, International Edition, 24: 224, 2010.
78. **Papadimitriou E.**, Koutsioumpa M. and Mikelis C. “The growth factor pleiotrophin induces migration of endothelial and tumour cells that express $\alpha_v\beta_3$ integrin and nucleolin on their cell surface”. *Copenhagen 16th World Congress of Basic and Clinical Pharmacology*, Copenhagen, Denmark, July 17-23, 2010. Basic & Clinical Pharmacology & Toxicology, 107 (Suppl. 1): 513, 2010 (Paper No.: 3318).

79. Daletos G., Lamprou M., Zoumpoulakis P., Zervou M., Assimomytis N.L., Geronikaki A., Papadimitriou E., Magafa V. and Cordopatis P. "Synthesis, evaluation and conformational solution studies of cysteine-based $\alpha_4\beta_1$ integrin ligands". *The 31st European Peptide Symposium*, Copenhagen, Denmark, September 5-9, 2010. Journal of Peptide Science 16 (S2): 159, 2010.
80. Frilligou E., **Papadimitriou E.** and Tselios T. "Microwave-assisted solid-phase peptide synthesis of the domain 60-110 of human pleiotrophin (hPTN) with two disulfide bonds on CLTR-CL resin" *The 31st European Peptide Symposium*, Copenhagen, Denmark, September 5-9, 2010. Journal of Peptide Science 16 (S2): 73, 2010.
81. Kaspiris A., Mikelis C., Khaldi L., Grivas T., Kouvaras I., Dangas S., Vasileiadis E. and **Papadimitriou E.** "Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta (RPTP β/ζ) in patients with osteoarthritis". *2010 World Congress on Osteoarthritis*, Brussels, Belgium, September 23-26, 2010. Osteoarthritis and Cartilage 18, Supplement 2: S77, 2010.
82. Koutsoumpa M., Mikelis C., Kieffer N., Skandalis S., Hellman U., Petrou C., Magafa V., Cordopatis P. and **Papadimitriou E.** "Cell surface expression of nucleolin is stimulated by $\alpha_v\beta_3$ integrin activation and is required for pleiotrophin-induced cell migration". *4th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 2-4, 2011. Angiogenesis 14: 80, 2011.
83. Bountouris P. and **Papadimitriou E.** "Effect of anti-diabetic drug rosiglitazone in pleiotrophin-induced endothelial cell activation". *4th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 2-4, 2011. Angiogenesis 14: 87, 2011.
84. Kouroufexi A., Theophanous-Kitiri S., Polykarpou G., Leotsinidis M., Kardamakis D., **Papadimitriou E.** "Use of granulocyte growth factor in an elderly population receiving chemotherapy and radiotherapy". *"Advances and perspectives in Geriatric Oncology"*, Athens, Greece, February 17-18, 2012. Forum of Clinical Oncology Special Edition: 15, 2012.
85. Kaspiris A., **Papadimitriou E.**, Chronopoulos E., Vasiliadis E., Khaldi L., Kouvaras I., Lamprou M. "Immunolocalization of the human metalloelastase MMP-12 in the cartilage and subchondral bone in osteoarthritis". *39th Annual Congress of ECTS*, Stockholm, Sweden, May 19-23, 2012. Bone 50 (Supplement 1): S185, 2012.
86. Giannopoulou E., Kotsirilou D., Nikolakopoulos A., **Papadimitriou E.**, Makatsoris T., Kalofonos H. "The impact of EGF on Notch protein levels in non-small cell lung cancer". *22nd Biennial Congress of the European Association for Cancer Research*, Barcelona, Spain, July 7-10, 2012. Eur J Cancer 48: S115, 2012.
87. Zervou M., Potamitis C., Zoumpoulakis P., Fotakis C., **Papadimitriou E.**, Cordopatis P., Magafa V. "Pharmacophore model of cysteine-based $\alpha_4\beta_1$ integrin ligands based on conformational solution studies". *32nd European Peptide Symposium*, Athens, Greece, September 2-7, 2012. Εάδα-βήρυξ: Journal of Peptide Science 18 : S165, 2012.
88. **Papadimitriou E.**, Koutsoumpa M., Poimenidi E., Theodoropoulou C., Kieffer N., Courty J. "Angiogenic growth factor-induced cell surface expression of nucleolin and cell migration depend on $\alpha_v\beta_3$ integrin expression". *22nd European Tissue Repair Society Meeting*, Athens, Greece, October 4-5, 2012. Wound Repair Regen 20(5): A105, 2012.
89. Nikolakopoulos A., Kotsirilou D., Giannopoulou E., **Papadimitriou E.**, Makatsoris T. and Kalofonos, H.P. "Inhibition of Notch pathway in non-small cell lung cancer". *11th International Congress on Targeted Anticancer Therapies (TAT 2013)*, Paris, France, March 4-6, 2013. Ann Oncol 24 (suppl 1): i21-i22, 2013.
90. Lamprou M., Sarigiannis Y., Bakandritsos A., Avgoustakis K., Winnefeld F., Pispas S., Meristoudi A., Zboril R. and **Papadimitriou E.** "Effects of poly(methacrylic acid)-graft-poly(ethylene glycol) coated magnetic nanoparticles on drug delivery to endothelial and cancer cells". *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14 2014. Angiogenesis 17 (3): 758, 2014.

91. Lamprou M. and **Papadimitriou E.** “Putative role of vascular endothelial growth factor receptor 2 in pleiotrophin-induced endothelial cell migration”. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14 2014. *Angiogenesis* 17 (3): 752, 2014.
92. Koutsioumpa M., Poimenidi E., Theodoropoulou C., Pantazaka E., Skoura A., Megalooikonomou V., Kieffer N., Courty J., Sugahara K. and **Papadimitriou E.** “A role of receptor protein tyrosine phosphatase beta/zeta in vascular endothelial growth factor-induced endothelial cell migration”. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14 2014. *Angiogenesis* 17 (3): 754, 2014.
93. Poimenidi E., Theodoropoulou C., Koutsioumpa M., van den Broek M., Koolwijk P. and **Papadimitriou E.** “VEGF decreases expression and secretion of pleiotrophin in a receptor protein tyrosine phosphatase beta/zeta and cell surface nucleolin-dependent manner”. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14 2014. *Angiogenesis* 17 (3): 754, 2014.
94. Lampropoulou E., Logoviti I., Koutsioumpa M. and **Papadimitriou E.** “Cyclin-dependent kinase 5 is involved in pleiotrophin-induced endothelial cell migration”. *40th FEBS Congress, The Biochemical Basis of Life, Berlin, Germany*, July 4-9, 2015. *FEBS Journal* 282 (Suppl. 1): 221, 2015.
95. Lamprou M., Sarigiannis Y., Bakandritsos A., Avgoustakis K., Winnefeld F., Pispas S., Meristoudi A. and **Papadimitriou E.** “Drug delivery to human endothelial and glioblastoma cells by poly(methacrylic acid)-graft-poly(ethylene glycol)-coated magnetic nanoparticles”. *40th FEBS Congress, The Biochemical Basis of Life, Berlin, Germany*, July 4-9, 2015. *FEBS Journal* 282 (Suppl. 1): 266, 2015.

Abstracts in conference proceedings

International Conferences

1. **Papadimitriou E.**, Lelkes P.I., Maragoudakis M.E. and Unsworth B.R. “Quantitative analysis of basement membrane formation during embryonic development of the chick chorioallantoic membrane”. *5th International Congress on Cell Biology*, P-6.1, Madrid, Spain, July 1992.
2. Chick D.M., Lelkes P.I., **Papadimitriou E.** and Unsworth B.R. “Organ-specificity of endocrine microvascular endothelium: Heterotypic interactions with parenchymal cells and selective lectin staining”. *5th International Congress on Cell Biology*, P-14.6, Madrid, Spain, July 1992.
3. Lelkes P.I., Chick D.M., **Papadimitriou E.** and Samet M.M. “Successful *in vitro* endothelialization of the luminal surface of an artificial blood pump”. *3rd Biennial Meeting of ISACB on “Toward application of advances in basic cardiovascular biology”*, St. Louis, MO, USA. ISACB meeting abstracts, November 1992.
4. Lelkes P.I., Chick D.M., Samet M.M., **Papadimitriou E.**, Smith L.M., Christensen C.N. Hendricks M., Verhoeven M.L. and Calahan P.T. “Successful endothelialization of the blood contacting surface in an artificial blood pump”. *Proceedings of Cardiovascular Science and Technology Conference*, page 234, December 1992.
5. **Papadimitriou E.**, Unsworth B.R., Maragoudakis M.E. and Lelkes P.I. “Quantitative analysis of extracellular matrix formation”. *Proceedings of Scientific Day Conference*, Sinai Samaritan Medical Center, Milwaukee, Wisconsin, USA, page 2, June 1993.
6. Lelkes P.I., **Papadimitriou E.**, Nikolaychik V., Chick D.M. and Samet M.M. “Endothelialization of the luminal surface of an artificial blood pump”. *Proceedings of Scientific Day Conference*, Sinai Samaritan Medical Center, Milwaukee, Wisconsin, USA, page 3, June 1993.
7. **Papadimitriou E.** and Lelkes P.I. “Thrombin increases extracellular matrix deposition in cultured endothelial cells”. *Scientific Conference on the Molecular and Cellular Biology of the Vascular Wall*, American Heart Association, Boston, MA, USA, October 1993.

8. Lelkes P.I., **Papadimitriou E.**, Manolopoulos V.G., Hayman G.T., Unsworth B.R. and Maragoudakis M. E. "Modulation of extracellular matrix protein deposition from rat adrenal medullary endothelial cells by thrombin and cAMP-elevating agonists". *World Congress on in vitro biology, 1996 Meeting of the Society for in vitro biology*, San Francisco, CA, USA, June 22-27, 1996.
9. **Papadimitriou E.**, Kritikou D., Mavroidis M., Zacharopoulou A. and Mintzas A. "The Heat Shock 70 Genes of the medfly *Ceratitis capitata*: Gene organization and structure". *XXth International Congress of Entomology*. Firenze. Italy, 1996.
10. **Papadimitriou E.**, Ioannou P. and Antimisiaris S. "Interactions of liposomes with cells in culture" NATO Advanced Study Institute: "Targeting of drugs: Strategies for stealth therapeutic systems", Sounio, Greece, June 24 - July 5, 1997.
11. **Papadimitriou E.**, Maragoudakis M. E. and Pipili-Synetos E. "Role of platelets, nitric oxide and cell adhesion molecules in the formation of tubes by endothelial cells *in vitro*". *NATO Advanced Study Institute "Angiogenesis: Models, Modulators and Clinical Applications"*, Rhodes, Greece, June 20-30, 1997.
12. **Papadimitriou E.**, Maragoudakis M.E., Waters C., Manolopoulos V.G., Unsworth B.R. and Lelkes P.I. "Regulatory mechanisms of extracellular matrix protein deposition by cultured endothelial cells". *3^{eme} Reunion du reseau francais d'angiogenese*, Toulouse, France, April 24-25, 1998.
13. **Papadimitriou E.**, Courty J. and Katsoris P. "HARP induces angiogenesis: *in vitro* and *in vivo* studies." *5th Biannual International Conference "Angiogenesis: From the molecular to integrative pharmacology"*, Crete, Greece, July 1-7, 1999.
14. Kokolakis G., **Papadimitriou E.**, Chrysanthis G., Rojas-Gil A.P., Kalosaka B., Chrysanthakopoulou B., Zacharopoulou A. and Mintzas A. "Heat shock puffs, genes and promoters in the Mediterranean fruit fly *Ceratitis capitata*". *3rd International Workshop on the Transgenesis of Invertebrate Organisms*, Crete, Greece, 1999.
15. Papaioannou S., Hadjimichael C., Kardamakis D., **Papadimitriou E.**, Panagiotopoulou M. and Demopoulos J. "Antiangiogenetic mechanisms of X-rays". *ΙΑΟΪ Advanced Study Institute "Vascular Endothelium: Source and Target of Inflammatory Mediators"*, Crete, Greece, June 24 - July 5, 2000.
16. Gortzi O., **Papadimitriou E.**, Ioannou P. and Antimisiaris S.G. "Effect of arsonolipid containing liposomes on viability of cancerous and non-cancerous cells in culture", *Proceedings of the 27th International Symposium on Controlled Release Materials*, Porte Maillot, France, July 7-13, 2000.
17. **Papadimitriou E.**, Heroult M., Courty J., Polykratis A., Stergiou C. and Katsoris P. "Endothelial cell proliferation induced by HARP: Implication of N or C terminal peptides". *XVIIth FECTS Meeting*, Patras, Greece, July 1-5, 2000.
18. Giannopoulou E., Katsoris P., Kardamakis D., Papaioannou S. and **Papadimitriou E.** "Radioprotective effect of amifostine on the vascular system". *European School of Oncology, Tumour Angiogenesis: Implications in prognosis and treatment of cancer*, Alexandroupolis, Greece, October 27-28, 2000.
19. **Papadimitriou E.**, Courty J., Polykratis A., Stergiou C. and Katsoris P. "Angiogenic effects of HARP and implication of the two terminal peptide"s. *European School of Oncology, Tumour Angiogenesis: Implications in prognosis and treatment of cancer*, Alexandroupolis, Greece, October 27-28, 2000.
20. Kallinteri P., **Papadimitriou E.** and Antimisiaris S. "Interactions of asialoglycopeptide bearing liposomes with HepG2 cells". *2nd Mediterranean meeting: New perspectives in controlled release*, Athens, Greece, April 28-29, 2001.
21. Gortzi O., **Papadimitriou E.**, Antimisiaris S. and Ioannou P. "Arsoliposomes: a novel class of liposomes with anticancer potential". *2nd Mediterranean meeting: New perspectives in controlled release*, Athens, Greece, April 28-29, 2001.

22. **Papadimitriou E.**, Giannopoulou E., Parthymou A., Hatziapostolou M., Kardamakis D., Kotsaki E., Polytarchou C., Papaioannou S. and Katsoris P. "X-Rays modulate ECM composition and tumor growth". *6th Biannual International Conference "Angiogenesis: Basic Science and Clinical Developments"*, Crete, Greece, June 26 - July 2, 2001.
23. Hatziapostolou M., **Papadimitriou E.**, Giannopoulou E. and Katsoris P. "Implication of plasmin in angiogenesis". *6th Biannual International Conference "Angiogenesis: Basic Science and Clinical Developments"*, Crete, Greece, June 26 July 2, 2001.
24. Polyrkratis A., Heroult M., **Papadimitriou E.**, Courty J. and Katsoris P. "Plasmin alters the biological actions of HARP". *6th Biannual International Conference "Angiogenesis: Basic Science and Clinical Developments"*, Crete, Greece, June 26 July 2, 2001.
25. Polytarchou C., Katsoris P., Kardamakis D. and **Papadimitriou E.** "The role of free radical scavengers in angiogenesis". *6th Biannual International Conference "Angiogenesis: Basic Science and Clinical Developments"*, Crete, Greece, June 26 July 2, 2001.
26. Koletsis E., Fotopoulos V., Chatzimichalis A., Kokkinis K., **Papadimitriou E.**, Karadimou A., Marinos E., Bellenis I. and Dougenis D. "State of the Art Lecture, Organ Transplantation". *2nd International Conference on Heme Oxygenase (HO/CO)*, Catania, Sicily, Italy, June 6-9, 2002.
27. Koletsis E., Chatzimichalis A., **Papadimitriou E.**, Kokkinis K., Fotopoulos V., Melachrinou M., Marinos E., Bellenis I. and Dougenis D. "Administration of exogenous free SP-A Surfactant results in an enhancing graft preservation properties in experimental lung transplantation". *5th International Congress on Lung Transplantation*, Paris, France, September 19-20, 2002.
28. Koletsis E., Chatzimichalis A., Kokkinis K., **Papadimitriou E.**, Melachrinou M, Marinos E., Bellenis I. and Dougenis D. "Pretreatment of donor lung with surfactant in an autotransplantation pig model: effect on PVR, NO, alveoli and graft elasticity". *16th Annual Meeting of the European Association for Cardio-Thoracic surgery*, Monaco, September 22-25, 2002.
29. Koletsis E., Chatzimichalis A., Kokkinis K., Melachrinou M., **Papadimitriou E.**, Marinos E., Bellenis I. and Dougenis D. "In situ lung autotransplantation. A studying model for ischaemia - reperfusion injury". *European Society of Thoracic surgeons 10th Annual Meeting, 10th European Conference on General Thoracic Surgery*, Istanbul, Turkey, October 26-28, 2002.
30. **Papadimitriou E.**, Polyrkratis A., Karetso E., Kokolakis G., Courty J., Mikelis C. and Katsoris P. "Regulation of angiogenesis by the growth factor HARP". *EU Workshop on Cellular Transport Strategies for targeting of Epitopes, Drugs and Reporter Molecules*, Budapest, Hungary, March 6-9, 2003.
31. Mikelis C., Polyrkratis A., Katsoris P., Zompra A., Cordopatis P., Courty J. and **Papadimitriou E.** "Synthesis and biological actions of a synthetic peptide that corresponds to the C-terminal region of HARP". *EU Workshop on Cellular Transport Strategies for targeting of Epitopes, Drugs and Reporter Molecules*, Budapest, Hungary, March 6-9, 2003.
32. Polyrkratis A., **Papadimitriou E.**, Courty J. and Katsoris P. "Identification of HARP domains with potential activities on angiogenesis *in vitro*". *EU Workshop on Cellular Transport Strategies for targeting of Epitopes, Drugs and Reporter Molecules*, Budapest, Hungary, March 6-9, 2003.
33. Mikelis C., Polyrkratis A., Katsoris P., Zompra A., Cordopatis P., Courty J. and **Papadimitriou E.** "Synthesis and biological actions of a synthetic peptide that corresponds to the C-terminal region of HARP". *7th Biannual International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Crete, Greece, July 2-8, 2003.
34. Mikelis C., Bakopanos K., Pavlopoulos G., Katsoris P., Wdzieczak-Bakala J. and **Papadimitriou E.** "Effect of the tetrapeptide AcSDKP and analogues on angiogenesis in the chicken embryo chorioallantoic membrane *in vivo*". *7th Biannual International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Crete, Greece, July 2-8, 2003.
35. Parthymou A., Pavlopoulos G., Kardamakis D. and **Papadimitriou E.** "Irradiation of C6 glioma cells with X rays increases the expression of angiogenic genes and the angiogenic activity *in vitro*". *7th*

Biannual International Conference “Angiogenesis: Basic Science and Clinical Applications”, Crete, Greece, July 2-8, 2003.

36. Fousteris M.A., Manioudakis M.E., **Papadimitriou E.P.** and Nikolaropoulos S.S. “Anti-proliferative activity of pyrrolocarbazole analogues of the indolocarbazole skeleton of natural products against glioblastoma multiform cell lines”. *7th International Symposium on Predictive Oncology and Intervention Strategies*, Nice, France, February 7-10, 2004.
37. Polytarchou C.P. and **Papadimitriou E.P.** “Dexamethasone differentially affects angiogenesis *in vivo* and *in vitro*”. *XIXth Meeting of the Federation of the European Connective Tissue Societies*, Termina-Giardini Naxos, Italy, July 9-13, 2004.
38. HatziaPOSTOULOU M.N., Katsoris P. and **Papadimitriou E.P.** “Effect of the growth factor HARP on the induction of solid tumors in the human prostate”. *XIXth Meeting of the Federation of the European Connective Tissue Societies*, Termina-Giardini Naxos, Italy, July 9-13, 2004.
39. Polykratis A.E., Katsoris P.G. and **Papadimitriou E.P.** “HARP induces migration of human endothelial cells through the PI3K-MAPK pathway”. *XIXth Meeting of the Federation of the European Connective Tissue Societies*, Termina-Giardini Naxos, Italy, July 9-13, 2004.
40. Pyriochou A., Polytarchou C., **Papadimitriou E.** and Papapetropoulos A. “Soluble guanylyl cyclase activation promotes angiogenesis”. *2nd International Conference on cGMP: cGMP Generators and Effectors*, Potsdam, Germany, June 10-12, 2005.
41. Polytarchou C., HatziaPOSTOULOU M., Papadopoulou A., Poimenidi E., Mikelis C. and **Papadimitriou E.** “The role of eNOS in hydrogen peroxide-induced pleiotrophin up-regulation and endothelial cell activation”. *3rd International Meeting on Angiogenesis*, VU University Medical Center, Amsterdam, The Netherlands, March 1-3, 2007.
42. **Papadimitriou E.** “Angiogenesis in health and disease”. *FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, Greece, May 21-26, 2007.
43. **Papadimitriou E.** “Heparin affin regulatory peptide/pleiotrophin as a new target for therapy of tumours or/and other angiogenesis-based diseases”. *FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, Greece, May 21-26, 2007.
44. Koutsoumpa M., HatziaPOSTOULOU M. and **Papadimitriou E.** “Effects of aprotinin on human endothelial and cancer cells biological activities”. *FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, Greece, May 21-26, 2007.
45. Mikelis C. and **Papadimitriou E.** “Regulation of angiogenesis by heparin affin regulatory peptide”. *FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, Greece, May 21-26, 2007.
46. **Papadimitriou E.** “Pleiotrophin as a possible new target for therapy of angiogenesis-related diseases and cancer”. *Carla Workshop on “Proteoglycans and glycosaminoglycans as therapeutic targets and tools”*, Soreze, France, October 2-3, 2007.
47. Mikelis C. and **Papadimitriou E.** “Novel mechanism that mediates the angiogenic properties of pleiotrophin through interaction with integrin $\alpha_v\beta_3$ and MMP-2”. *Keystone Symposia on Molecular and Cellular Biology “Molecular Mechanisms of Angiogenesis in Development and Disease”*, Vancouver, Canada, January 15-20, 2008.
48. Mikelis C. and **Papadimitriou E.** “Novel mechanism that mediates the angiogenic properties of pleiotrophin through $\alpha_v\beta_3$ integrin”. *8th Euroconference on Angiogenesis*, Paris, France, May 9-12, 2008.

49. **Papadimitriou E.** “Pleiotrophin as a new target for therapy of angiogenesis-based diseases and cancer”. *9th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Conference and Cultural Center of the University of Patras, Patras, Greece, June 22-26, 2008.
50. Mikelis C. and **Papadimitriou E.** “Integrin $\alpha_v\beta_3$ is a principal mediator of PTN-induced endothelial cell migration”. *9th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Conference and Cultural Center of the University of Patras, Patras, Greece, June 22-26, 2008.
51. Drosou G., Mikelis C., Theochari K., Vourtsis D., Giannopoulou E., Katsoris P. and **Papadimitriou E.** “The role of endogenous pleiotrophin expression in angiogenesis in vivo”. *9th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Conference and Cultural Center of the University of Patras, Patras, Greece, June 22-26, 2008.
52. Tsirmoula S. and **Papadimitriou E.** “Role of reactive oxygen species on the stimulatory effect of pleiotrophin on human endothelial cell migration”. *9th International Conference “Angiogenesis: Basic Science and Clinical Applications”*, Conference and Cultural Center of the University of Patras, Patras, Greece, June 22-26, 2008.
53. **Papadimitriou E.**, Mikelis C., Koutsoumpa M. and Theodoropoulou C. “Receptor Protein Tyrosine Phosphatase beta/zeta as a possible new target to regulate endothelial and tumor cell migration”. *EHRlich II: 2nd World Conference on Magic Bullets*, Nuremberg, Germany, October 3-5, 2008.
54. Daletos G., Magafa V., Panagoulis A., Lamprou M., **Papadimitriou E.**, Geronikaki A. and Cordopatis P. “Synthesis and biological evaluation of cyclic peptides of $\alpha_4\beta_1$ integrin antagonists”. *Biologically active peptides XI*, Czech Republic, April 22-24, 2009.
55. Koutsoumpa M., Mikelis C., Kieffer N., Skandalis S., Hellman U., Petrou C., Magafa V., Cordopatis P. and **Papadimitriou E.** “A role of nucleolin in the $\alpha_v\beta_3$ integrin-mediated pleiotrophin-induced cell migration”. *2nd FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, July 11-16, 2009.
56. Tsirmoula S. and **Papadimitriou E.** “Implication of reactive oxygen species in the stimulatory effect of pleiotrophin in human cell migration”. *2nd FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, July 11-16, 2009.
57. Mikelis C., Koutsoumpa M., Theochari K., Tsirmoula S., Kieffer N., Zompra K., Cordopatis P., Koutsoumbas A.G., Vradis A.A. and **Papadimitriou E.** “Interaction of pleiotrophin with $\alpha_v\beta_3$ integrin determines its effect on endothelial and tumor cell migration”. *2nd FEBS Advanced Lecture Course “Matrix Pathobiology, Signaling and Molecular Targets”*, Conference and Cultural Center of the University of Patras, Patras, July 11-16, 2009.
58. Tsirmoula S., Skandalis S., Hellman U. and **Papadimitriou E.** “Role of moesin and reactive oxygen species in pleiotrophin-stimulated endothelial cell migration”. *8th International Symposium on the Biology of Endothelial Cells*, Zurich, Switzerland, June 15-18, 2011.
59. Kotsirilou D., Giannopoulou E., **Papadimitriou E.**, Makatsoris T. and Kalofonos H.P. “Targeting Notch in non small cell lung cancer (NSCLC) and its implication in epidermal growth factor receptor (EGFR)”. *28th International Conference “Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells”*, Mykonos, Greece, June 20-22, 2011.
60. Kotsirilou D., Giannopoulou E., **Papadimitriou E.**, Makatsoris T. and Kalofonos H.P. “The role of Notch in non small cell lung cancer (NSCLC) and its implication in epidermal growth factor receptor (EGFR)”. *1st International Conference “Notch Targeting in Cancer”*, Mykonos, Greece, June 22-24, 2011.
61. Koutsoumpa M., Mikelis C., Kieffer N., Petrou C., Magafa V., Cordopatis P. **Papadimitriou E.** “Receptor protein tyrosine phosphatase beta/zeta forms a functional complex with $\alpha_v\beta_3$ integrin and

cell surface nucleolin required for pleiotrophin-induced cell migration”. *Europhosphatases 2011: “Protein Phosphatases. From molecules to networks”*, Baden near Vienna, Austria, July 18-23, 2011.

62. Kouroufexi A., Theophanous-Kitiri S., Polykarpou G. , Leotsinidis M., Kardamakis D., **Papadimitriou E.** “Use of granulocyte growth factor in an elderly population receiving chemotherapy and radiotherapy”. “Advances and perspectives in Geriatric Oncology”, Athens, Greece, February 17-18, 2012.

63. Tsoukala P., Magoulas G.E., Antoniou A., Athanassopoulos C.M., Papaioannou D., **Papadimitriou E.**, Tsigkou T. and Lamprou M.”Synthesis of artemisinin dimers and their biological evaluation against MCF7 breast cancer cells”. *Proceedings of the 5th BBBB International Conference*, Athens, Greece, September 26-28, 2013.

64. Koutsioumpa M., Poimenidi E., Theodoropoulou C. and **Papadimitriou E.** “Receptor protein tyrosine phosphatase beta/zeta is a regulator of vascular endothelial growth factor-induced endothelial cell migration”. *4th FEBS Advanced Lecture Course on Matrix Pathobiology, Signaling and Molecular Targets*, Kos, Greece, September 26-October 1, 2013.

65. Sarigiannis Y., Bakandritsos A., Lamprou M., **Papadimitriou E.**, Voulgari E., Avgoustakis K., Winnefeld F., Pispas S., Moundrichas G., Zboril R., Tucek J. “Derivatization of Magnetic Nanoparticles with Poly(methacrylic acid)-graft-poly(ethylene glycol), and the Effects of the Molecular Structure on Drug Delivery”. *International Conference on Nanotechnology in Medicine*, Royal Free Hospital, University College London, UK, February 26-28, 2014.

66. Tsirmoula S., Lamprou M., **Papadimitriou E.** “Xanthine oxidase inhibition abolishes pleiotrophin-induced endothelial cell migration”. *Pharmacology 2014 (British Pharmacological Society)*, Queen Elizabeth II Conference Centre, London, UK, December 16-18, 2014.

67. Koutsioumpa M., Poimenidi E., Pantazaka E., Theodoropoulou C., Papadimitriou E. “Receptor protein tyrosine phosphatase beta/zeta mediates vascular endothelial growth factor (VEGF) receptor-independent actions of VEGF”. *Pharmacology 2014 (British Pharmacological Society)*, Queen Elizabeth II Conference Centre, London, UK, December 16-18, 2014.

Greek Conferences: 81

CURRENT TEACHING ACTIVITIES

Undergraduate courses:

- Pharmacology I and II
- Molecular Pharmacology
- Introduction to Pharmaceutical Sciences

Postgraduate courses:

- Advanced Molecular Pharmacology
- Drug Interactions – Toxicology
- Molecular Pharmacology-Immunology (Department of Chemistry, University of Patras)

Supervisor:

2 postdoctoral fellows

12 PhD theses (9 completed)

44 MSc theses (35 completed 9 in progress)

25 final year pre-graduate Experimental Theses (24 completed, 1 in progress)

33 final year pre-graduate Literature Theses

Present academic appointments of former PhD students/post-docs:

Efstathia Giannopoulou: Research Assistant, Clinical Oncology Lab, Dept of Medicine, University of Patras, Greece.

Apostolos Polykratis: Postdoctoral fellow at University of Cologne, CECAD Research Center, Germany

Anastassia Parthymou: Research Assistant, Endocrinology Lab, Dept of Medicine, University of Patras, Greece.

Christos Polytarchou: Reader in Health and Disease, Interdisciplinary Biomedical Research Centre, School of Science and Technology, Nottingham Trent University, UK.

Maria Hatziapostolou: Lecturer in Epigenetics, Centre for Biological Sciences, University of Southampton, UK.

Constantinos Mikelis: Assistant Professor, Biomedical Sciences Department, School of Pharmacy, Texas Tech University, USA

Evgenia Lampropoulou: Postdoctoral fellow at Biomedical Research Foundation of the Academy of Athens, Greece.

Marina Koutsioumpa: Postdoctoral fellow at UCLA, USA.

Sotiria Tsirmoula: Community pharmacist.

BOOKS/TEACHING MATERIAL

“**Angiogenesis: Basic Science and Clinical Applications**”, Editor (co-editor with emeritus Professor Dr. M.E. Maragoudakis), Transworld Research Network, ISBN: 978-81-7895-302-1, 2007.

“**Molecular Pharmacology**”, author, Parisianou A.E., Athens, Greece, ISBN: 978-960-394-609-0, 2010.

“**General Principles in Pharmacology**”, author, University of Patras, 1999, 2001.

“**Laboratory of Molecular Pharmacology**” notes, author, University of Patras, 2000, 2001, 2003, 2005, 2008.

“**Introduction to Pharmaceutical Sciences**” notes, University of Patras, 2008 (co-author with C. Avgoustakis and G. Pairas).

“**Lecture Notes: Clinical Pharmacology and Therapeutics**” by Gerald A. McKay, John L. Reid and Matthew R. Walters (translated and edited in Greek, Parisianou A.E., Athens, Greece, ISBN: 978-960-394-980-0, 2014).

“**Pharmacology, 7th Edition**” by Humphry P. Rang, Maureen M. Dale, James M. Ritter, Rod Flower and Graeme Henderson (participation in translation and Greek edition, Parisianou A.E., Athens, Greece, ISBN: 978-960-394-923-7, 2014).

INTERNATIONAL COLLABORATORS

- Dr. Jose Courty, at Universite Paris 12 Val de Marne, Paris, France.
- Dr. Pieter Koolwijk, at VU University Medical Centre, Amsterdam, The Netherlands.
- Dr. Nelly Kieffer at Jiao Tong University Medical School, Shanghai, China.
- Drs. Christos Polytarchou and Maria Hatziapostolou at Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
- Dr. Kazuyuki Sugahara, at Hokkaido University Graduate School of Life Sciences, Kita-ku, Sapporo, Japan.
- Dr. Peter Giannoudis, Academic Unit of Orthopaedic and Trauma Surgery, University of Leeds, UK.